Combined liraglutide and metformin therapy in overweight or obese women with polycystic ovary syndrome: A systematic review and meta‐analysis

作者：Jing Ling, Tiantian Wang, Wenrui Huang, Yuhua Zhen, Mingzi Zhang, Xingzi Fang, Wencong Song, Xuelian Du · 发表于：Diabetes Obesity and Metabolism · 年份：2025 · DOI：10.1111/dom.70028 · 被引用次数：8 · 研究领域：Ovarian function and disorders、Hypothalamic control of reproductive hormones、Growth Hormone and Insulin-like Growth Factors

PURPOSE: Overweight or obese women with polycystic ovary syndrome (PCOS) often experience significant metabolic and hormonal disturbances. This systematic review and meta-analysis evaluated whether liraglutide combined with metformin is more effective than metformin alone in improving glycaemic control, lipid metabolism, body mass index (BMI) and sex hormone profiles in this population. METHODS: We systematically searched PubMed, EMBASE, the Cochrane Library, China National Knowledge Infrastructure, Weipu, SinoMed and Wanfang Data for randomised controlled trials (RCTs) comparing liraglutide plus metformin to metformin monotherapy in overweight or obese women with PCOS. Primary outcomes included fasting plasma glucose (FPG), 2-h postprandial glucose, HbA1c, fasting insulin, homeostasis model assessment of insulin resistance (HOMA-IR), BMI, sex hormones (luteinising hormone [LH], follicle-stimulating hormone [FSH], total testosterone [TT]) and lipid profiles (total cholesterol [TC], triglycerides [TG], low-density lipoprotein cholesterol [LDL-C] and high-density lipoprotein cholesterol [HDL-C]). Subgroup analyses were conducted by treatment duration, lifestyle intervention and baseline BMI. RESULTS: = 95%), 2-h postprandial glucose (-2.87, [-3.70, -2.05]; 97%), HbA1c (-2.91, [-3.84, -1.98]; 96%), HOMA-IR (-2.29, [-2.98, -1.60]; 97%) and fasting insulin (-0.75, [-1.41, -0.09]; 94%). BMI was also significantly reduced (-1.64, [-2.38, -0.89]; 97%). Hormonal indicators improved, i...